Regeneron Pharmaceuticals, Inc. (LON: 0R2M)
London
· Delayed Price · Currency is GBP · Price in USD708.66
0.00 (0.00%)
At close: Dec 23, 2024
Regeneron Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 29, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 30, 2022 | Dec '21 Dec 30, 2021 | Dec '20 Dec 30, 2020 | Dec '19 Dec 30, 2019 | 2018 - 2014 |
| Operating Revenue | 13,299 | 12,581 | 11,808 | 15,791 | 7,940 | 6,384 | Upgrade
|
| Other Revenue | 548.1 | 536.1 | 365.1 | 281.2 | 557 | 174 | Upgrade
|
| Revenue | 13,847 | 13,117 | 12,173 | 16,072 | 8,497 | 6,558 | Upgrade
|
| Revenue Growth (YoY) | 5.72% | 7.76% | -24.26% | 89.14% | 29.58% | 27.44% | Upgrade
|
| Cost of Revenue | 6,819 | 6,255 | 5,153 | 5,298 | 3,767 | 3,215 | Upgrade
|
| Gross Profit | 7,028 | 6,862 | 7,020 | 10,774 | 4,730 | 3,343 | Upgrade
|
| Selling, General & Admin | 2,900 | 2,631 | 2,116 | 1,825 | 1,346 | 1,342 | Upgrade
|
| Other Operating Expenses | -0.5 | -2.1 | -89.9 | -45.6 | -280.4 | -209.2 | Upgrade
|
| Operating Expenses | 2,899 | 2,629 | 2,026 | 1,779 | 1,066 | 1,133 | Upgrade
|
| Operating Income | 4,129 | 4,233 | 4,994 | 8,995 | 3,665 | 2,210 | Upgrade
|
| Interest Expense | -63 | -73 | -59.4 | -57.3 | -56.9 | -30.2 | Upgrade
|
| Interest & Investment Income | 677 | 495.9 | 160.1 | 45.8 | 75.4 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -12.9 | -12.9 | 50.2 | 0.4 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 6 | -20 | 8.8 | 4 | 19.3 | 131.2 | Upgrade
|
| EBT Excluding Unusual Items | 4,736 | 4,623 | 5,154 | 8,988 | 3,702 | 2,311 | Upgrade
|
| Gain (Loss) on Sale of Investments | 388.9 | -237.8 | -39.8 | 386.1 | 196 | 118.3 | Upgrade
|
| Other Unusual Items | -37.9 | - | - | - | - | - | Upgrade
|
| Pretax Income | 4,969 | 4,199 | 4,859 | 9,326 | 3,810 | 2,429 | Upgrade
|
| Income Tax Expense | 314.9 | 245.7 | 520.4 | 1,251 | 297.2 | 313.3 | Upgrade
|
| Net Income | 4,655 | 3,954 | 4,338 | 8,075 | 3,513 | 2,116 | Upgrade
|
| Net Income to Common | 4,655 | 3,954 | 4,338 | 8,075 | 3,513 | 2,116 | Upgrade
|
| Net Income Growth | 16.62% | -8.87% | -46.28% | 129.86% | 66.05% | -13.44% | Upgrade
|
| Shares Outstanding (Basic) | 108 | 107 | 107 | 106 | 108 | 109 | Upgrade
|
| Shares Outstanding (Diluted) | 115 | 114 | 114 | 112 | 115 | 115 | Upgrade
|
| Shares Change (YoY) | 1.16% | 0.18% | 1.16% | -2.52% | 0.44% | -0.17% | Upgrade
|
| EPS (Basic) | 43.26 | 37.05 | 40.51 | 76.40 | 32.65 | 19.38 | Upgrade
|
| EPS (Diluted) | 40.43 | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | Upgrade
|
| EPS Growth | 15.31% | -9.03% | -46.89% | 135.81% | 65.33% | -13.29% | Upgrade
|
| Free Cash Flow | 3,440 | 3,875 | 4,425 | 6,529 | 2,004 | 2,000 | Upgrade
|
| Free Cash Flow Per Share | 29.88 | 34.08 | 38.99 | 58.19 | 17.41 | 17.46 | Upgrade
|
| Gross Margin | 50.75% | 52.32% | 57.67% | 67.04% | 55.67% | 50.97% | Upgrade
|
| Operating Margin | 29.81% | 32.27% | 41.03% | 55.97% | 43.13% | 33.70% | Upgrade
|
| Profit Margin | 33.61% | 30.14% | 35.64% | 50.25% | 41.35% | 32.26% | Upgrade
|
| Free Cash Flow Margin | 24.84% | 29.54% | 36.35% | 40.63% | 23.58% | 30.51% | Upgrade
|
| EBITDA | 4,598 | 4,654 | 5,335 | 9,281 | 3,901 | 2,420 | Upgrade
|
| EBITDA Margin | 33.21% | 35.48% | 43.83% | 57.75% | 45.90% | 36.91% | Upgrade
|
| D&A For EBITDA | 469.5 | 421 | 341.4 | 286.2 | 235.9 | 210.3 | Upgrade
|
| EBIT | 4,129 | 4,233 | 4,994 | 8,995 | 3,665 | 2,210 | Upgrade
|
| EBIT Margin | 29.81% | 32.27% | 41.03% | 55.97% | 43.13% | 33.70% | Upgrade
|
| Effective Tax Rate | 6.34% | 5.85% | 10.71% | 13.41% | 7.80% | 12.90% | Upgrade
|
| Revenue as Reported | 13,847 | 13,117 | 12,173 | 16,072 | 8,497 | 6,558 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.